# QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy

> clinical trial · VERIFIED · 2026-08-26

Status: NOT_YET_RECRUITING · Sponsor: Hebei Medical University Fourth Hospital · Condition: Breast Cancer

- Company: Hebei Medical University Fourth Hospital
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07782840

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.